Human APRIL (A Proliferation-Inducing Ligand, also known as TNFSF13, CD256, or TALL-2) is a member of the tumor necrosis factor (TNF) superfamily that plays a key role in regulating B cell survival, proliferation, and antibody production. APRIL is primarily produced by myeloid cells such as monocytes, macrophages, dendritic cells, and neutrophils, and signals through the receptors TACI (TNFRSF13B) and BCMA (TNFRSF17), activating downstream pathways including NF-κB and MAPK that promote B cell maturation and plasma cell survival. APRIL functions closely with the related TNF family cytokine BAFF (B cell–activating factor, TNFSF13B), and together they regulate humoral immunity and long-lived antibody responses. In human health, APRIL is important for maintaining immunoglobulin production and mucosal immunity but is also implicated in pathological conditions when dysregulated, including autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and multiple sclerosis, as well as B cell malignancies such as multiple myeloma and certain lymphomas. Because APRIL supports plasma cell survival and tumor growth in some cancers, it has become an important therapeutic target in immunology and oncology. Characterization of human APRIL supports research into B cell biology, antibody-mediated immunity, autoimmune disease mechanisms, and development of targeted therapies that modulate TNF superfamily signaling.